ArticleAntimicrobial agents and chemotherapy2012
In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 72 citations in OpenAlex.
- LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2015Trial
- Next-Generation Antimicrobial Peptides for Biofilm-Associated Infections: Engineering, Biomaterial Delivery and AI-Assisted Discovery.Antibiotics (Basel, Switzerland) · 2026Review
- Discovery and Development of Voxvoganan: First-in-Class Synthetic Antimicrobial Peptidomimetic.Journal of medicinal chemistry · 2026Review
- Lack of Spontaneous and Adaptive Resistance Development inAntibiotics (Basel, Switzerland) · 2025Article
- Review
- Multiple-Layer Chitosan-Based Patches Medicated With LTX-109 Antimicrobial Peptide for Modulated Local Therapy in the Management of Chronic Wounds.Macromolecular bioscience · 2025Article
- Therapeutic peptide development revolutionized: Harnessing the power of artificial intelligence for drug discovery.Heliyon · 2024Review
- Antimicrobial Peptides: The Game-Changer in the Epic Battle Against Multidrug-Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Recent Advances in Amphipathic Peptidomimetics as Antimicrobial Agents to Combat Drug Resistance.Molecules (Basel, Switzerland) · 2024Review
- PreventingACS applied materials & interfaces · 2024Article
- Treatment of MRSA Infection: Where are We?Current medicinal chemistry · 2024Review
- Peptide Flexibility and the Hydrophobic Moment are Determinants to Evaluate the Clinical Potential of Magainins.The Journal of membrane biology · 2023Article
- Staph wars: the antibiotic pipeline strikes back.Microbiology (Reading, England) · 2023Review
- Lateral membrane organization as target of an antimicrobial peptidomimetic compound.Nature communications · 2023Article
- Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections.Microbial biotechnology · 2023Review
- S100 Proteins as Novel Therapeutic Targets in Psoriasis and Other Autoimmune Diseases.Molecules (Basel, Switzerland) · 2022Review
- Antimicrobial Peptides in Early-Life Host Defense, Perinatal Infections, and Necrotizing Enterocolitis-An Update.Journal of clinical medicine · 2022Review
- Design, characterization and structure-function analysis of novel antimicrobial peptides based on the N-terminal CATH-2 fragment.Scientific reports · 2022Article
- Atomic-Resolution Structures and Mode of Action of Clinically Relevant Antimicrobial Peptides.International journal of molecular sciences · 2022Review
- Antimicrobial Peptides with Antibacterial Activity against Vancomycin-ResistantInternational journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
LTX-109 and eight other antimicrobial agents were evaluated against 155 methicillin-resistant Staphylococcus aureus (MRSA) isolates, including strains resistant to vancomycin and strains with decreased susceptibility to daptomycin and linezolid, by microdilution tests to determine MICs. Time-kill assays were performed against representative MRSA, vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant S. aureus (VRSA) isolates. LTX-109 demonstrated a MIC range of 2 to 4 μg/ml and dose-dependent rapid bactericidal activity against S. aureus. This activity was not influenced by resistance to other antistaphylococcal agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.